- TV Footage
- Integrated Annual Reports
- Quarterly Statements
- Sustainability Report
- Newsletter Overview
- Social Media
- Media Contact
Monheim, December 12, 2019 – Bayer's Neptra® ear drops solution for dogs (florfenicol, terbinafine hydrochloride, mometasone furoate) has now received a marketing authorization for Europe.
Neptra® is approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.
“Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian,” says Mario Andreoli, Head of Marketing at Bayer Animal Health. “Neptra® offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice.”
No at-home applications by the dog owner are required. The treatment stays in the hands of the veterinarian and thus allows full control over compliance. “With Neptra® we provide a high-quality veterinary treatment,” explains Andreoli, “that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application.”
Bayer Animal Health complements its veterinary product portfolio with an innovative product for the effective treatment of ear infections in dogs. Neptra® will be available on the European market in early 2020.
Neptra® is an effective treatment for otitis externa (ear infections in dogs), offering a key advantage: It only requires one application for full treatment. It is administered by the vet during consultation and requires no at-home application of medicine by pet owners. This ensures treatment compliance and is convenient for the vet and the dog owner.
About otitis externa
Otitis externa is an inflammation of the outer ear that often causes severe pain or irritation. Yeast and bacterial infections often accompany this inflammation and are the focus of most ear treatments. Otitis externa in dogs can have many causes, incl. allergies, ear mites, environmental factors and plant material caught in the ear.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center